NPC-32

NPC-32 is an investigational platelet aggregation inhibitor currently in preclinical development by Nobelpharma. It is being developed for applications in cardiovascular surgery and emergency care settings. The primary therapeutic goal of NPC-32 is to inhibit the aggregation of platelets, thereby preventing the formation of thrombi (blood clots) which can lead to serious complications such as myocardial infarction or stroke during surgical procedures or acute cardiovascular crises. As of early 2026, Nobelpharma has not publicly disclosed the specific molecular target or the chemical structure of NPC-32, but it is categorized as a new drug candidate within their pipeline addressing unmet needs in acute care and surgical medicine.

Other names

platelet aggregation inhibitor